Clinical trials: Apixaban
Hemorrhage, Surgical, Hemorrhage Postoperative
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery
- Conditions
- Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
- Trial name
- STAR-D (NCT05093504)
- Testing
- DrugSorb-ATR system
- Where
- 27 sites in United States
- Volunteers
- 9 people
- Sponsor
- CytoSorbents, Inc
Nephrotic Syndrome, Proteinuria
Pharmacokinetics of Apixaban in Nephrotic Syndrome
This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.
- Trial name
- NCT02599532
- Testing
- apixaban
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cancer-associated Thrombosis
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with…
- Trial name
- API-CAT (NCT03692065)
- Testing
- Apixaban 5 MG
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 1,766 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anticoagulant-induced Bleeding, Periodontal Diseases
Evaluation of the Intra- and Post- Operative Bleeding After Periodontal Debridement in Direct Anticoagulant Patients
Direct Oral Anticoagulants were recently approved for medical treatment of several condition such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting sometimes the conventional oral…
- Trial name
- NOADB_db (NCT03124004)
- Testing
- periodontal debridement
- Where
- Italy
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Trieste
Thrombophilia
Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal
Direct oral anticoagulants (DOAC) are anticoagulant molecules that act either directly on factor Xa (Apixaban, Rivaroxaban) or on factor IIa (Dabigatran).
- Trial name
- DOAC-Stop (NCT06171984)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Healthy Volunteers
Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy…
- Trial name
- NCT02034578
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation.
- Trial name
- AVERROES (NCT00496769)
- Testing
- Apixaban, Acetylsalicylic acid
- Where
- 503 sites in United States, Argentina and 34 more
- Volunteers
- 6,421 people
- Sponsor
- Bristol-Myers Squibb
Anticoagulation Treatment
Register for New Oral Anticoagulants
Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in routine treatment will recorded in this register.
- Trial name
- NOAC (NCT01588119)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- GWT-TUD GmbH
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Evaluate the Safety and Efficacy of Apixaban
A Multi-center Study of Apixaban(APPROACH)
The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid) postoperatively.
- Trial name
- NCT04550637
- Testing
- Oral apixaban
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Nonvalvular Atrial Fibrillation
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
The main objective of this study is to realize an observational "real life" study conducted in French geriatric settings, to assess safety and efficacy in ≥ 80 year-old patients with nonvalvular Atrial fibrillation (AF) newly…
- Trial name
- SOFIA (NCT04586972)
- Where
- France
- Volunteers
- 977 people
- Sponsor
- Gérond'if
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Venous Thromboembolism, Venous Thromboses
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
After hip or knee replacement all patients receive a standardized treatment with blood thinners, this medication is called thrombosis prophylaxis.
- Conditions
- Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- DISTINCT (NCT06581965)
- Testing
- Short duration prophylaxis, Higher intensity and longer duration prophylaxis, Control
- Where
- 13 sites in Netherlands
- Volunteers
- 10,078 people
- Sponsor
- Leiden University Medical Center
Covid19, Corona Virus Infection
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
Since the end of 2019, Egypt and the whole world have been suffering from the Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Conditions
- Covid19, Corona Virus Infection, Hypercoagulability
- Trial name
- NCT04736901
- Testing
- Enoxaparin, Rivaroxaban, Apixaban
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Atrial Fibrillation, Stroke
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- PACES (NCT04045665)
- Testing
- Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
- Where
- 106 sites in United States, Brazil and 3 more
- Volunteers
- 3,200 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Deep Vein Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban…
- Trial name
- NCT00371683
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 3,608 people
- Sponsor
- Bristol-Myers Squibb
Transient Ischemic Attack, Stroke
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
- Conditions
- Transient Ischemic Attack, Stroke, Atrial Fibrillation
- Trial name
- AREST (NCT02283294)
- Testing
- Apixaban, Warfarin
- Where
- 5 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of South Florida
Venous Thromboembolism, Major Bleed
Direct Oral Anticoagulants and Venous Thromboembolism
The purpose of this study is to determine whether use of direct oral anticoagulants (DOACs) is associated with an increased risk of major bleeding compared to warfarin use, for the treatment of venous thromboembolism (VTE).
- Trial name
- NCT02833987
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 59,525 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Atrial Fibrillation on Apixaban Treatment
Application-Delivered Patient Education in Enhancing the Usage of Apixaban in Patients With Atrial Fibrillation
"AF is the most common arrhythmia, with an overall prevalence of approximately 2%. It is particularly prevalent in individuals over 60 years old, affecting about 5% of this population.
- Trial name
- NCT06869083
- Testing
- AF application enhancing AF education and drug adhrence, AF application without enhancing AF education and drug adhrence
- Where
- South Korea
- Volunteers
- 5,200 people
- Sponsor
- Yonsei University